Skip to main content


Editor's pick

Most patients with Down’s syndrome will have dementia at the time of death

Down's syndrome karyotype

Dementia is the proximate cause of death in 70% of older adults with Down’s syndrome, show findings from a large community-based study published in JAMA Neurology.

ECTRIMS 2018: Ongoing relapse activity is a suitable treatment target in secondary-progressive multiple sclerosis

Nathaniel Lizak presents study findings showing that ongoing relapse in patients with multiple sclerosis is not a contraindication to disease-modifying treatment (2:19).

ECTRIMS 2018: Better outcomes in relapsing MS patients switching to natalizumb versus fingolimod after first-line treatment

Tim Spelman discusses his team’s findings of a significant reduction in relapse rates and greater disability improvement in multiple sclerosis patients who relapse on first-line treatment and switch to natalizumab versus fingolimod (2:55).

ECTRIMS 2018: Focal cortical damage identifies MS patients at increased risk of frequent early relapses

Antonio Scalfari gives an overview of findings showing that early focal cortical lesions at multiple sclerosis onset is associated with earlier relapse and an increased risk of converting to secondary progressive multiple sclerosis (4:14).  

ECTRIMS 2018: Focal inflammatory brain disease associated with increased risk for cognitive disability

Wallace Brownlee talks about his group’s findings that conventional MRI measures of inflammatory disease could help identify patients with early multiple sclerosis who are at high risk of developing cognitive disability (3:05).

ECTRIMS 2018: Real-world data support early treatment initiation in relapsing-remitting MS patients

Pietro Iaffaldano shares his real-world findings from the Big Multiple Sclerosis Data Network showing an optimal time to treatment initiation of 6 months in patients with relapsing-remitting multiple sclerosis (1:51).

ECTRIMS 2018: McDonald 2017 criteria allows for earlier MS diagnosis than McDonald 2010 in patients with clinically isolated syndrome

Wallace Brownlee presents his study showing that the revised McDonald 2017 criteria are more sensitive than the McDonald 2010 criteria, albeit with a modest reduction in specificity, for diagnosing multiple sclerosis in patients with typical clinically isolated syndrome characteristics (3:49).

ECTRIMS 2018: Sensitivity for predicting a second MS episode increased with McDonald 2017 criteria

Roos M van der Vuurst de Vries discusses her McDonald 2017 criteria findings, which provide further support of improved sensitivity for diagnosing clinically definite multiple sclerosis in patients with clinically isolated syndrome (5:05).

ECTRIMS 2018: : ORATORIO extension-phase trial findings show sustained reduction in MS disability progression with ocrelizumab

Jerry Wolinksy summarises his findings from the open-label extension period of the phase III ORATORIO trial looking at sustained disability progression with ocrelizumab in patients with primary progressive multiple sclerosis (8:20).

ECTRIMS 2018: Novel 3-in-1 MS-SMART trial fails on efficacy end-points but paves the way for multi-arm strategies

13-12-2018 | Neurology | Main feed | News

Biomarkers predict cognitive impairment risk

US researchers have used population-based data to predict an individual’s absolute risk of developing cognitive impairment according to imaging-based biomarkers of amyloid and neuronal injury.


Ann Neurol 2018; doi:10.1002/ana.25388

29-11-2018 | Alzheimer's disease | News | Article

Global burden of dementia estimated

The number of people living with dementia globally has more than doubled between 1990 and 2016, estimates the Global Burden of Disease Study 2016.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30403-4

Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30456-3

15-11-2018 | Alzheimer's disease | News | Article

CSF neurofilament light a ‘preferred’ biomarker for MCI progression

Elevated cerebrospinal fluid neurofilament light levels are associated with an increased risk of mild cognitive impairment, indicate findings from a population-based study.


JAMA Neurol 2018; doi:10.1001/jamaneurol.2018.3459

08-11-2018 | Neurology | Main feed | News

Global burden of motor neuron diseases quantified

High-income countries currently have the highest rates of motor neuron diseases worldwide, and the burden is increasing with the ageing population, shows an analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study 2016.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30404-6
Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30398-3

01-11-2018 | Parkinson's disease | News | Article

Dopamine to levodopa-carbidopa switch reduces impulse control disorders in PD

Switching from dopamine agonists to levodopa-carbidopa slow-release formulations reduces impulse control disorders in patients with Parkinson’s disease, shows a multicentre study.


J Neurol Neurosurg Psychiatry 2018; doi:10.1136/jnnp-2018-318942

J Neurol Neurosurg Psychiatry 2018; doi:10.1136/jnnp-2018-319375

25-10-2018 | Multiple sclerosis | News | Article

Medicinal cannabinoids show small antispastic and analgesic benefits for MS patients

The benefits of medicinal cannabinoids for the treatment of spasticity, pain and bladder dysfunction in patients with multiple sclerosis may be limited, suggests a systematic review and meta-analysis.


JAMA Network Open 2018; 1(6): e183485

JAMA Network Open 2018;1(6): e183484

Twitter Icon Follow medwireNews

Click here
image credits